Daily Endocrinology Research Analysis
A multicenter randomized trial found that intensive LDL-C lowering with evolocumab did not reduce saphenous vein graft disease after CABG, challenging assumptions about lipid-driven early graft failure. Multi-omics profiling revealed macronutrient-specific postprandial hormone–metabolite networks that improve insulin resistance prediction, supporting precision nutrition. Integrative human microbiome plus real-world data linked hypothyroidism to higher SIBO risk—mitigated by levothyroxine—and ide
Summary
A multicenter randomized trial found that intensive LDL-C lowering with evolocumab did not reduce saphenous vein graft disease after CABG, challenging assumptions about lipid-driven early graft failure. Multi-omics profiling revealed macronutrient-specific postprandial hormone–metabolite networks that improve insulin resistance prediction, supporting precision nutrition. Integrative human microbiome plus real-world data linked hypothyroidism to higher SIBO risk—mitigated by levothyroxine—and identified distinct duodenal coliform signatures.
Research Themes
- Cardiometabolic therapeutics and residual risk after LDL-C lowering
- Thyroid–gut microbiome axis and small intestinal bacterial overgrowth
- Postprandial multi-omics for precision nutrition and insulin resistance
Selected Articles
1. Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.
In this multicenter double-blind RCT after CABG, evolocumab achieved a 48.4% placebo-adjusted LDL-C reduction but did not lower the 24-month saphenous vein graft disease rate compared with placebo. Safety was similar between groups, suggesting that mechanisms other than LDL-driven atherosclerosis dominate early SVG failure.
Impact: A large, well-designed RCT in a top journal delivers a definitive negative result that redirects secondary prevention strategies after CABG away from LDL-C intensification for graft patency.
Clinical Implications: Do not expect PCSK9 inhibition to improve early SVG patency; focus on surgical technique, conduit selection, antithrombotic strategies, and non-lipid mechanisms (e.g., thrombosis, intimal hyperplasia). LDL-C lowering remains essential for systemic atherosclerosis but not for early SVG failure.
Key Findings
- Evolocumab reduced LDL-C by a placebo-adjusted 48.4% at 24 months (-52.4% vs -4.0%).
- No reduction in 24-month vein graft disease rate: 21.7% (149/686) with evolocumab vs 19.7% (127/644) with placebo (p=0.44).
- Adverse event profiles were similar between evolocumab and placebo.
Methodological Strengths
- International, multicenter, randomized, double-blind, placebo-controlled design.
- Objective imaging-based primary endpoint assessed at a fixed 24-month timepoint.
Limitations
- Primary outcome available in a subset (554 participants), raising potential for missing data bias.
- Surrogate angiographic endpoint may not fully capture clinical graft function.
Future Directions: Investigate non-lipid drivers of early SVG failure (e.g., thrombosis, inflammation, intimal hyperplasia) and test targeted antithrombotic or antiproliferative strategies; evaluate conduit choices and surgical techniques in RCTs.
BACKGROUND: Saphenous vein graft (SVG) failure remains a substantial challenge after coronary artery bypass graft (CABG). LDL cholesterol (LDL-C) is a causal risk factor for atherosclerosis, but its role in SVG failure is not well established. We evaluated whether early initiation of intensive LDL-C lowering with evolocumab could reduce SVG failure. METHODS: NEWTON-CABG CardioLink-5 was a multicentre, double-blind, randomised, placebo-controlled trial conducted at 23 sites in Canada, the USA, Australia, and Hungary. Eligible participants were adults (age ≥18 years) who underwent CABG with at least two SVGs and were being treated with statin therapy of moderate or high intensity. Participants were randomly allocated (1:1; variable block size) within 21 days of CABG to subcutaneous evolocumab 140 mg or placebo every 2 weeks. The primary endpoint was the 24-month vein graft disease rate (VGDR; the proportion of SVGs with ≥50% occlusion on coronary CT angiography or clinically indicated invasive angiography) in the modified intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03900026, and is completed. FINDINGS: Between June 17, 2019, and Nov 10, 2022, 782 individuals were randomly assigned (389 to evolocumab and 393 to placebo). At baseline, among the 554 participants with primary outcome data available, the median age was 66 years (IQR 60-72), 471 (85%) of 554 participants were male and 83 (15%) were female, and the median LDL-C was 1·85 mmol/L (IQR 1·25-2·84) in the evolocumab group and 1·86 mmol/L (1·20-2·76) in the placebo group. Evolocumab resulted in a mean 48·4% placebo-adjusted reduction in LDL-C at 24 months (-52·4% vs -4·0%). The 24-month VGDR was 21·7% (149 of 686 grafts) in the evolocumab group and 19·7% (127 of 644 grafts) in the placebo group (difference 2·0% [95% CI -3·1 to 7·1]; p=0·44). Treatment was well tolerated, with similar adverse event profiles between the groups. INTERPRETATION: Among patients who underwent CABG, evolocumab did not reduce SVG disease at 24 months following the index surgery despite substantial LDL-C lowering. Further LDL-C lowering does not appear to meaningfully affect the pathophysiological mechanisms responsible for early SVG failure. FUNDING: Amgen Canada.
2. Dynamic multi-omics profiling of islet and gut hormonal secretion and peripheral crosstalk in response to various nutrient loads.
This human postprandial multi-omics study shows macronutrient-specific hormone–metabolite networks: incretin (GLP-1, GIP) dynamics are only captured postprandially, and protein load links most strongly to hepatic and muscular insulin resistance, whereas butter relates to systemic IR. Integrative models improved IR prediction over fasting data and identified candidate mediators linking α/β-cell function to IR.
Impact: Provides a mechanistic systems-level map of postprandial endocrine–metabolic crosstalk, enabling precision nutrition strategies and better phenotyping of insulin resistance beyond fasting metrics.
Clinical Implications: Supports designing macronutrient-tailored diets to target hepatic vs muscular insulin resistance phenotypes and leveraging postprandial multi-omics for risk stratification and monitoring of metabolic therapies including incretin-based agents.
Key Findings
- Incretins GLP-1 and GIP were exclusively explained by postprandial multi-omics, not fasting data.
- Protein load showed the strongest association with hepatic and muscular insulin resistance; butter linked to systemic IR.
- Postprandial multi-omics improved insulin resistance prediction and identified mediators linking α/β-cell function to IR.
Methodological Strengths
- Integrated multi-omics under controlled nutrient challenges capturing dynamic postprandial biology.
- Comparative analysis across distinct macronutrients with organ (hepatic) enrichment and linkage modeling.
Limitations
- Sample size and exact timing windows are not specified in the abstract, limiting generalizability assessment.
- Observational physiology limits causal inference; external validation in diverse cohorts is needed.
Future Directions: Test macronutrient-personalized diets guided by postprandial signatures in RCTs; validate mediators as therapeutic targets and as biomarkers for incretin and insulin-sensitizing therapies.
Postprandial metabolism is a complex and dynamic process involving diverse biomolecules, with islet and gut hormones playing crucial roles. However, how these hormones interact with biomolecules after nutrient intake and coordinate with peripheral insulin resistance (IR) remains elusive. This study characterizes postprandial multi-omics dynamics under mixed meals and four distinct macronutrient loads, investigating hormone secretion patterns, associated responsive molecules, and their relationships with IR. Postprandial multi-omics data significantly elucidate insulin and glucagon secretion, highlighting differences from the fasting state, while glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are exclusively explained postprandially. Hormone secretion and molecular responses exhibit substantial heterogeneity among macronutrients. Postprandial multi-omics better predict IR, particularly with hepatic enrichment. Protein load shows the strongest association with both hepatic and muscular IR, while butter mostly connects with systemic IR. Several identified molecules mediate interactions between IR and islet α and β cell function, providing a molecular basis for advancing precision nutrition therapies in metabolic diseases.
3. Relationship between hypothyroidism, risk of small intestinal bacterial overgrowth, and duodenal microbiome alterations.
Combining duodenal microbiome profiling with real-world data, hypothyroidism was associated with higher SIBO prevalence and 10-year incidence (RR ~2.2–2.4), and levothyroxine use attenuated this risk. Distinct duodenal coliform signatures (Klebsiella vs Escherichia/Shigella) and a Neisseria core in hypothyroid subjects suggest disease-specific microbial ecology.
Impact: Provides mechanistic and epidemiologic evidence linking thyroid dysfunction to SIBO with treatment-modifiable risk, informing GI evaluation in hypothyroid patients and highlighting microbiome targets.
Clinical Implications: Consider SIBO screening in hypothyroid patients with persistent GI symptoms; optimize levothyroxine therapy; recognize distinct microbial patterns that may influence antibiotic selection and adjunctive microbiome-directed therapies.
Key Findings
- Higher SIBO prevalence in hypothyroidism vs controls in REIMAGINE: 32.65% vs 15.17%.
- TriNetX 10-year SIBO risk was elevated: RR 2.20 (hypothyroidism, unspecified etiology) and RR 2.40 (autoimmune thyroiditis) vs matched controls.
- Levothyroxine use mitigated SIBO risk: RR 0.33 (HUE) and RR 0.78 (autoimmune thyroiditis).
- Distinct duodenal microbiome: Neisseria core in hypothyroid subjects; Klebsiella predominance in Hypo+/SIBO+ vs Escherichia/Shigella in Hypo-/SIBO+.
Methodological Strengths
- Dual approach combining duodenal 16S/metagenomic profiling with large-scale real-world incidence estimates.
- Use of propensity score matching to estimate 10-year SIBO risk differences.
Limitations
- Residual confounding in observational datasets; levothyroxine adherence and dosing not fully controlled.
- REIMAGINE microbiome sample size is modest, limiting subgroup analyses.
Future Directions: Prospective trials to test whether optimizing thyroid hormone replacement reduces SIBO incidence and symptoms; targeted microbiome interventions based on Klebsiella vs Escherichia-dominant profiles.
CONTEXT: There is an association between hypothyroidism and small intestinal bacterial overgrowth (SIBO), but the exact mechanistic link between these two conditions is not fully elucidated. OBJECTIVE: We evaluate the incidence and risks of subsequently developing SIBO, and changes in small bowel microbial populations, in subjects with hypothyroidism or autoimmune thyroiditis. DESIGN AND OUTCOME MEASURES: Duodenal aspirates from REIMAGINE study subjects with a history of hypothyroidism (hypothyroid group, N=49) and controls (N=323) underwent 16S rRNA sequencing (MiSeq, Illumina); a subset also underwent metagenomic sequencing (NovaSeq6000, Illumina). Separately, the TriNetX Analytics platform was used to evaluate ten-year cumulative incidences and relative risk [RR] of developing SIBO in subjects with hypothyroidism (unspecified etiology, HUE), and a subset with autoimmune thyroiditis, vs. propensity score matched (PSM) control groups. RESULTS: Among REIMAGINE subjects, SIBO prevalence was higher in the hypothyroid group (32.65%) vs. controls (15.17%). In the TriNetX analysis, ten-year cumulative incidences of SIBO were higher in HUE (RR=2.20) and autoimmune thyroiditis (RR=2.40) subjects vs. matched controls. However, these risks appeared to be mitigated both in HUE (RR=0.33) and autoimmune thyroiditis (RR=0.78) subjects taking levothyroxine. Analyzing the duodenal microbiome, genus Neisseria was part of the core microbiome in the hypothyroid group (Hypo+/SIBO-, Hypo+/SIBO+) but not in non-hypothyroid subjects (Hypo-/SIBO-, Hypo-/SIBO+). Increased prevalence of Gram-negative coliforms occurred in both SIBO+ groups, but Escherichia/Shigella formed part of the core in non-hypothyroid subjects (Hypo-/SIBO+), whereas Klebsiella species were prevalent in hypothyroid group subjects with SIBO (Hypo+/SIBO+). CONCLUSION: These findings suggest there is an increased risk for development of SIBO in individuals with a history of hypothyroidism which may be ameliorated by treatment, and may involve specific Gram-negative coliforms.